Transmedics
TMDX
Market cap $3.8B

112.46 USD

-12.32

9.87%

At close Jul 11, 4:00 PM EDT

After hours

113.00

+0.54

0.48%

1 day

-9.87%

5 days

-12.03%

1 month

-21.29%

3 months

39.56%

6 months

75.58%

Year to date

69.11%

1 year

-21.86%

5 years

548.18%

10 years

402.95%

About: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Employees: 728

Healthcare Medical Devices

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

31% more repeat investments, than reductions

Existing positions increased: 118 | Existing positions reduced: 90

30% more call options, than puts

Call options by funds: $70.5M | Put options by funds: $54.1M

14% more capital invested

Capital invested by funds: $2.3B [Q4 2024] → $2.62B (+$327M) [Q1 2025]

6.05% more ownership

Funds ownership: 109.76% [Q4 2024] → 115.82% (+6.05%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

4% less funds holding

Funds holding: 309 [Q4 2024] → 296 (-13) [Q1 2025]

15% less first-time investments, than exits

New positions opened: 53 | Existing positions closed: 62

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$145

29%

upside

Avg. target

$148

31%

upside

High target

$150

33%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Suraj Kalia	33%upside $150	Outperform Maintained	17 Jun 2025
Piper Sandler Matt O'Brien	29%upside $145	Overweight Reiterated	4 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about TMDX published over the past 30 days

The Motley Fool

Is TransMedics Stock a Buy After Short-Seller Drama?

Explore the exciting world of TransMedics (TMDX 0.97%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

Is TransMedics Stock a Buy After Short-Seller Drama?

The Motley Fool

2 Stocks That Have Doubled This Year and Are Still Worth Buying

Positive, company-specific developments have led to shares of TransMedics Group (TMDX 1.08%) and FuboTV (FUBO 2.32%) more than doubling this year, even as the S&P 500 is barely in the green since January. Investing wisdom advises us to buy low, and some might think that after a greater than 100% return in six months, it's too late to get in on these stocks.

2 Stocks That Have Doubled This Year and Are Still Worth Buying

The Motley Fool

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Zacks Investment Research

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy

TransMedics' Q1 results showcased explosive 48% revenue growth and margin recovery, reaffirming my bullish thesis on its OCS technology and logistics moat. Despite new risks like competition and logistics costs, TMDX's execution, clinical edge, and management's ambitious growth targets support long-term market dominance. Valuation remains compelling: strong EPS growth and frequent estimate beats can sustain premium multiples as it scales.

TransMedics' Turnaround: The Organ Transplant Leader Is Still A Buy

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach Out

Schaeffers Research

These 24 Stocks Are Ripe for a Short Squeeze

With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.

These 24 Stocks Are Ripe for a Short Squeeze

Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.

Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation

Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May

In May, three stocks that released earnings stood out due to their massive sales beats. These names are mid-cap companies with market capitalizations between $2 billion and $10 billion.

Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May

See News Rankings

Charts implemented using Lightweight Charts™